Dr. Reddy's Laboratories Ltd. - ADR (R1DY34)
B3 B3 Primary Summary
Dr. Reddy's Laboratories Ltd. - ADR (R1DY34) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dr. Reddy's Laboratories Ltd. - ADR ever had a stock split?
Dr. Reddy's Laboratories Ltd. - ADR Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Gunupati Venkateswara Prasad B.E. CEO | B3 Exchange | - ISIN |
| BR Country | 27,811 Employees | 9 Jul 2025 Last Dividend | 5 Nov 2024 Last Split | - IPO Date |
Overview
Dr. Reddy's Laboratories Limited, with its various subsidiaries, stands as a comprehensive pharmaceutical company with global operations. The business structure is divided into three main segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. Established in 1984, the company has its headquarters located in Hyderabad, India. Dr. Reddy’s engages in a broad spectrum of pharmaceutical services, including the production and marketing of branded and generic dosage forms, contract research, as well as the development of new therapies in critical areas such as oncology and inflammation. Through its dedicated efforts in the pharmaceutical industry, Dr. Reddy’s Laboratories aims to innovate and provide effective healthcare solutions worldwide.
Products and Services
- Global Generics:
Dr. Reddy’s Global Generics segment focuses on manufacturing and marketing a wide range of prescription and over-the-counter pharmaceutical products. These products are either marketed under a brand name or as generic dosages, ensuring therapeutic equivalence to branded formulations. This segment also encompasses the biologics business, representing the company’s venture into complex products derived from biological sources.
- Pharmaceutical Services and Active Ingredients (PSAI):
This segment is responsible for the production and marketing of active pharmaceutical ingredients (APIs) and intermediates, which are essential for creating finished pharmaceutical products. Dr. Reddy’s PSAI segment serves the pharmaceutical industry by offering contract research services, alongside the manufacture and sale of active pharmaceutical ingredients and steroids tailored to customer specifications. This service enables other companies to produce a variety of pharmaceutical products efficiently.
- Others:
The Others segment of Dr. Reddy’s Laboratories is concentrated on the development of new therapies, particularly in the fields of oncology and inflammation. Additionally, it is involved in the research and development of differentiated formulations. Beyond pharmaceutical development, this segment expands the company’s reach into providing digital healthcare solutions and information technology enabled business support services. This facet of Dr. Reddy’s aligns with the modern healthcare industry’s move towards digitalization and personalized patient care.
